Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Basilea partner Asahi Kasei starts phase 2 study of Cresemba in children in Japan

    Asahi Kasei Therapeutics has started a multicenter, open‑label phase 2 study in Japan of Cresemba (isavuconazole) in children at risk for invasive mycoses to evaluate safety and pharmacokinetics. Cresemba is already approved for pediatric patients in the US, Canada, Europe and China, but in Japan it is so far approved only for adults. Worldwide in‑market sales of Cresemba amounted to USD 782 million in the April 2025–March 2026 period. » More on finanzen.net


  • Asahi Kasei secures license for Noguchi ADC technology

    Asahi Kasei Life Science has acquired licensing rights for an ADC technology developed by the Noguchi Institute that enables control of drug–antibody ratio and binding sites and the conjugation of two different drugs to a single antibody. The partners plan joint research, commercialization and possible sublicensing to biopharma companies and CDMOs such as Bionova Scientific. Asahi Kasei will thereby strengthen its healthcare offering; InvestingPro rates the company as financially very strong and sees upside potential for the share price. » More on de.investing.com


  • Asahi Kasei acquires Aicuris for €780 million

    Asahi Kasei has signed a definitive agreement to acquire all shares of Aicuris Anti-infective Cures for around €780 million; closing is expected in the first quarter of fiscal 2026. The acquisition expands Asahi Kasei’s specialty pharma portfolio with three assets, including the already licensed Prevymis, Pritelivir — which is nearing FDA approval with a 2026 target — and AIC468, currently in Phase I with a planned launch in 2030. Asahi Kasei expects the transaction to contribute positively to operating income from fiscal 2028 after amortization, strengthening its position in transplantation, nephrology and severe infectious diseases. » More on de.investing.com


  • Asahi Kasei secures global exclusive license for novel agents against autoimmune diseases

    Asahi Kasei Pharma has signed an exclusive global licensing agreement with Alchemedicine for preclinical lead compounds to treat autoimmune diseases, obtaining worldwide rights for research, development, manufacturing and commercialization. The substances were identified using Alchemedicine’s HiSAP platform; the program is independent of a prior 2022 collaboration. The compound AK1960 was recently advanced into a phase‑I study. Asahi Kasei emphasizes its “open innovation” strategy to develop therapy candidates and strengthen its pharma growth target through 2030. » More on de.investing.com


  • Asahi Kasei increases earnings per share and revenue in latest quarter

    Asahi Kasei reported earnings per share of 40.03 JPY for the latest quarter, up from 27.65 JPY in the year‑ago quarter. Revenue was 774.90 billion JPY, an increase of 0.78% from 768.92 billion JPY in the year‑ago quarter. The figures come from the quarterly financial conference on February 4, 2026. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Asahi Kasei has already paid €0.12 in dividends. The last payout was in June.

Financials

In the last quarter, Asahi Kasei had revenue of €4.84bn and net profit of €271.38m
(EUR) September 2026
YoY
Revenue 4.84bn 12.33%
Gross profit 1.63bn 16.09%
Net profit 271.38m 1.25%
EBITDA 777.15m 10.54%

Fundamentals

Metric Value
Market capitalization
€11.85bn
Number of shares
1.33bn
52-week high/low
€10.90 - €7.13
Dividend yield
2.47%
Dividends TTM
€0.23
Next dividend
€0.14
Beta
0.67
P/E ratio
10.78
PEG ratio
0.27
P/B ratio
1.00
P/S ratio
0.63

Company profile

Asahi Kasei Corporation manufactures, processes, and sells chemical products in Japan and internationally. The company operates through three segments: Material, Homes, and Health Care. It provides caustic soda, chemical fertilizers, nitric acid, ammonia, acrylonitrile, methyl methacrylate, styrene, adipic acid, hexamethylene diamine, AH salt, propionitrile, sodium cyanide, acetonitrile, methacrylonitrile, cyclohexyl methacrylate, cyclohexanol, cyclohexane, and cyclohexene; polymers; chemical intermediates; additives; membranes and systems; clads and anchors; optical and printing materials; electronic materials; and lithium-ion battery and lead-acid battery separators. The company offers cupro fiber, lining fabric, stretch fiber, spunbond nonwovens, cupro nonwoven fabric, microfiber suede, oil-water separator, multifunctional nonwoven, deodorizing nonwoven, heat-press formable thermoplastic nonwoven, noise suppression sheet, nylon filaments, flame-resistant fiber, honeycomb fabric, cellulose nanobead, ecorise, biocradle, and bemliese products, as well as polymers; synthetic rubber; elastomers; kitchen and household products; cleaners; and packaging products. In addition, the company provides electronic devices; and autoclaved aerated concrete, foundation systems, insulation materials, and structural systems and components. Further, it involved in the construction of homes and apartments; management of rental units and condominiums; brokerage of used homes; remodeling; and mortgage financing, asset management services, and insurance products. Additionally, the company provides pharmaceuticals and diagnostic reagents; dialyzers; therapeutic apheresis; biotherapeutics and plasma derivative filters and equipment, and virus removal filters; leukocyte reduction filters; defibrillators, temperature management systems, and data solutions; and UVC LED products. Asahi Kasei Corporation was founded in 1922 and is headquartered in Tokyo, Japan.

Name
Asahi Kasei
CEO
Koshiro Kudo
Headquarters Tokyo, ty
Japan
Website
IPO
04/01/2000
Employees 47,895

Ticker symbols

Exchange Symbol
Japan Exchange Group
3407.T
Pnk
AHKSF
Frankfurt
ASAA.F
DĂĽsseldorf
ASAA.DU
MĂĽnchen
ASAA.MU
🍪

Parqet  uses cookies. Learn more